NCT06874140CompletedPhase 1
Proteomic Study of Chuanhong Zhongfeng Capsule in the Treatment of ACI
Biomarkers and Potential Mechanisms of Chinese Medicine Compound (Chuanhong Zhongfeng Capsule) in the Treatment of Acute Cerebral Infarction
Source: ClinicalTrials.gov · Last updated 13 Mar 2025
Brief summary (registry, in English)
Acute cerebral infarction is characterized by high disability rate and high recurrence rate, which poses a great threat to the life and health of the nation. Proteomics technology is a holistic and comprehensive understanding of disease mechanism, cell metabolism and other processes at the protein level. The correlation between acute cerebral infarction and proteomics has become a hot spot of clinical and basic research in recent years. Chuanhong Zhongfeng capsule was developed by Ren Jixue, a master of national medicine, and clinical studies have confirmed that it not only promotes the recovery of neurological function in patients with cerebral infarction, reduces the disability rate, but also improves the long-term prognosis, but its mechanism of action and its target are still unclear. In the present study, we applied 4D Label-free proteomics technology and PRM technology to study for the first time the mechanism of action and potential targets of Chuanhong Zhongfeng Capsule in the treatment of acute cerebral infarction, which will provide a direction for the study of traditional Chinese medicine compounding for the prevention and treatment of cerebral infarction.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 26 Feb 2025
- Start date
- 1 Jan 2022
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- Yingyue Ding
- Diseases
- Stroke
- NCT number
- NCT06874140
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 20
- From 1 Jan 2022 to the primary completion date, 1 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnosis of hemorrhage or other pathological brain disorders based on head CT or MRI;
- Allergic individuals, those who are allergic to the test medication or the associated medicinal flavors or components thereof;
- Those with severe liver or kidney function impairment. -
Age
- Age \<40 years or \>80 years;
Who the study is looking for
- Meet the diagnostic criteria for ischemic stroke in the Chinese Guidelines for Diagnosis and Treatment of Ischemic Stroke in the Acute Phase 2018.
- Meet the diagnostic criteria for ischemic stroke in Chinese medicine.
- Within 2 weeks of acute onset of ischemic stroke.
- 4 ≤ NIHSS score \<15.
- Age 40-80 years old. -
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Changchun | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.